Mark Yarchoan
Johns Hopkins University
H-index: 38
North America-United States
Top articles of Mark Yarchoan
Expanding immunotherapy options in cholangiocarcinoma: Role of CD27 against in combination with PD-L1 and MEK inhibition on antitumor effect and CD8+ T cells
2024/1/20
Megen Wittling
H-Index: 1
Mark Yarchoan
H-Index: 27
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Cancer Research Communications
2024/4/18
Mark Yarchoan
H-Index: 27
Steven Smith
H-Index: 14
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Nature medicine
2024/4/7
Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update
2010/4
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
2024/2/29
Mark Yarchoan
H-Index: 27
Myron Schwartz
H-Index: 53
Abstract CT016: Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of …
Cancer Research
2024/4/5
Abstract CT022: Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study
Cancer Research
2024/4/5
The obesity paradox in immune checkpoint blockade: A pan-tumor analysis
Cancer Research
2024/3/22
Machine learning integrating spatial omics uncovers humoral immunity patterns in intratumoral tertiary lymphoid structures in pancreatic cancer pathologic responders
Cancer Research
2024/3/22
Integrating spatial multi-omics data with spatial quantitative pharmacology (spQSP) model to simulate human neoadjuvant immunotherapy clinical trial of hepatocellular carcinoma
Cancer Research
2024/3/22
Personalized neoantigen DNA vaccine GNOS-PV02 and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma
Cancer Research
2024/3/22
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Annals of Oncology
2024/2/19
Exploring the impact of IDH1-mutations on antitumor immunity in intrahepatic cholangiocarcinoma
Cancer Research
2024/3/22
Jae W Lee
H-Index: 3
Mark Yarchoan
H-Index: 27
B-cell activating factor (BAFF) enhances antitumor immunity
Cancer Research
2024/3/22
Mark Yarchoan
H-Index: 27
Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma …
2024/1/20
Identification of a novel morphology of tertiary lymphoid structure in patients with hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade
Cancer Research
2024/3/22
Jae W Lee
H-Index: 3
Sarah Mitchell
H-Index: 17
Qingfeng Zhu
H-Index: 15
Hao Wang
H-Index: 29
Mark Yarchoan
H-Index: 27
Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.
2024/1/20
Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune checkpoint …
Cancer Research
2024/3/22
Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD (L) 1 therapy.
2024/1/20
Mari Nakazawa
H-Index: 11
Amy Thomas
H-Index: 3
Hao Wang
H-Index: 29
Steven Dykstra
H-Index: 4
Mark Yarchoan
H-Index: 27
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma
Cell Reports Medicine
2024/3/19
Co-Authors
